<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018481</url>
  </required_header>
  <id_info>
    <org_study_id>21-605</org_study_id>
    <nct_id>NCT05018481</nct_id>
  </id_info>
  <brief_title>HA35 Moderate Alcoholic Hepatitis (AH) Study</brief_title>
  <official_title>Mechanism of HA35 in Patients With Alcoholic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible participants will be asked to take a placebo/treatment capsule for 90 days and&#xD;
      participate in two in-person study visits, one at the start of the 90 days and the second at&#xD;
      the completion of study supplement administration. Both visits will include a physical exam,&#xD;
      clinical labs, body composition measurements, muscle strength tests, questionnaires, and&#xD;
      urine and stool collections. Additionally, a sugar cocktail will be consumed to measure gut&#xD;
      permeability and a muscle biopsy will be collected. The day after the visits, you will need&#xD;
      to return to drop off the 24-hour urine collection.&#xD;
&#xD;
      Two phone visits will be performed in between the in-person visits at day 30 and 60 where you&#xD;
      will be asked a series of questionnaires as well as asked about study supplement compliance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Written informed consent will be obtained during the baseline visit (day 1). Patients will&#xD;
      given a physical exam and a blood test will be obtained if not in their medical chart. The&#xD;
      subjects who meet the criteria after the screening visit will have the following procedures:&#xD;
      A. Body composition will be quantified by whole-body dual energy X-ray absorptiometry (DEXA),&#xD;
      Bioelectric Impedance Analysis (BIA), chair stands, 3 position balance and hand grip strength&#xD;
      by dynamometry. B. Muscle biopsy from the lateral portion of vastus lateralis, about 20 cm&#xD;
      above knee, C. Questionnaires, D. Blood collection, E. Collection of stool samples, F. Sugar&#xD;
      cocktail administration, and G. Urine collection (24 hour)&#xD;
&#xD;
      After baseline measures have been completed, patients will be randomized in a 1:1 ratio to&#xD;
      either standard of care (SOC) + HA35 or SOC + placebo (140 mg/d) for a total of 3 months post&#xD;
      enrollment.&#xD;
&#xD;
      The subjects will be recalled after 3 months. The visit and the procedures conducted on day&#xD;
      90 will be similar to the baseline study visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare percent change of skeletal muscle mass</measure>
    <time_frame>Baseline to 90 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>HA35 Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>24 study participants will receive the standard of care treatment for AH and a 90-day supply of a placebo to take once a day with breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA35 Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 study participants will receive the standard of care treatment for AH and a 90-day supply of a HA35 to take once a day with breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate</intervention_name>
    <description>Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants</description>
    <arm_group_label>HA35 Treatment Group</arm_group_label>
    <other_name>HA35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo will be given in capsule form to study participants</description>
    <arm_group_label>HA35 Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Clinical diagnosis of alcoholic hepatitis defined as:&#xD;
&#xD;
          -  Regular consumption of alcohol with an intake of &gt;60 g daily or &gt;420 g weekly on&#xD;
             average for men and &gt;40 g daily or &gt;280 g weekly on average for women for 6 months or&#xD;
             more&#xD;
&#xD;
        AND&#xD;
&#xD;
          -  MELD &lt;21&#xD;
&#xD;
          -  Serum total bilirubin &gt;3 mg/dL&#xD;
&#xD;
          -  AST &gt;50 IU/I; AST:ALT ratio &gt;1.5; Both AST and ALT &lt;400 IU/I&#xD;
&#xD;
        OR Histologic evidence of AH.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients with gastrointestinal bleeding within 2 weeks&#xD;
&#xD;
          -  Active infection (positive blood or ascitic fluid culture)&#xD;
&#xD;
          -  Overt encephalopathy&#xD;
&#xD;
          -  Renal failure and/or on dialysis&#xD;
&#xD;
          -  Medications that alter muscle protein metabolism&#xD;
&#xD;
          -  Myopathies&#xD;
&#xD;
          -  Other end-stage organ diseases&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Solid organ or hematopoietic transplantation&#xD;
&#xD;
          -  Active alcohol withdrawal or ongoing participation in a Clinical Institute Withdrawal&#xD;
             Assessment (CIWA) protocol&#xD;
&#xD;
          -  History of recent upper gastrointestinal resection within past 6 months&#xD;
&#xD;
          -  Acute or chronic liver disease due to other active causes, in addition to alcoholic&#xD;
             liver disease&#xD;
&#xD;
          -  Inability to provide consent&#xD;
&#xD;
          -  Creatinine &gt;2mg/dL&#xD;
&#xD;
          -  Platelets &lt;60,000k/ul&#xD;
&#xD;
          -  PT/INR &gt;1.7&#xD;
&#xD;
          -  Presence of pedal edema&#xD;
&#xD;
          -  Use of anti-platelet/anticoagulation drugs or medications that interfere with blood&#xD;
             clotting&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Srinivasan Dasarathy, MD</last_name>
    <phone>216-318-7010</phone>
    <email>dasaras@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Bellar</last_name>
    <email>bellara@ccf.org</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Srinivasan Dasarathy</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

